foxo4 dri senolytic peptide study 2017 cell The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI Peptide - 10 mg
FOXO4 DRI Peptide 10 mg Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link Buy FOXO4 DRI (Proxofim) Senolytic Peptide For Cellular Renewal Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
Pay in 4 interest-free payments of $6.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




